

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.




As rescanning documents *will not* correct images,
please do not report the images to the
Image Problems Mailbox.

THIS PAGE BLANK (USPTO)



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : C07D 219/06, A61K 31/435</p>	<p>A1</p>	<p>(11) International Publication Number: WO 98/52923 (43) International Publication Date: 26 November 1998 (26.11.98)</p>
<p>(21) International Application Number: PCT/EP98/02991 (22) International Filing Date: 22 May 1998 (22.05.98) (30) Priority Data: 9710612.4 23 May 1997 (23.05.97) GB (71) Applicant (for all designated States except US): GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): SHARP, Matthew, Jude [GB/US]; Glaxo Wellcome Inc., Five Moore Drive, Research Triangle Park, NC 27709 (US). MADER, Catherine, J. [US/US]; Trimeris Inc., 4727 University Drive, Durham, NC 27707 (US). STRACHAN, Calum [GB/GB]; Glaxo Wellcome plc, Cobden Street, Montrose DD10 8EA (GB). (74) Agent: STOTT, Michael, J.; Glaxo Wellcome plc, Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</p>
<p>(54) Title: SYNTHESIS OF ACRIDINE DERIVATIVE MULTIDRUG-RESISTANT INHIBITORS</p>		



(57) Abstract

Synthesis of the MDRI of formula (I) from intermediates of acridone acid of formula (II) and aminophenethyl isoquinoline of formula (III), via steps including coupling and conversion to yield the MDRI of formula (I).

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

SYNTHESIS OF ACRIDINE DERIVATIVE MULTI DRUG RESISTANT INHIBITORS

BACKGROUND OF THE INVENTION

This invention relates to an improved process for preparing acridine derivatives. In particular it relates to the synthesis of compounds which are capable of sensitizing multidrug-resistant cancer cells to chemotherapeutic agents.

The multidrug-resistant inhibitor (MDRI), chemically known as N-{4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)-ethyl]phenyl}-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide and its physiologically acceptable salts is described in World Patent Application WO 92/12132, filed in the name of Laboratories Glaxo S.A. and published July 23, 1992 and also described in World Patent Application WO 96/11007, filed in the name of Glaxo Wellcome Inc. and published April 18, 1996. The compounds are disclosed as being useful in sensitizing multidrug-resistant cancer cells to chemotherapeutic agents.

In WO 92/12132, an acridine derivative was disclosed as synthesized by reacting compounds in the presence of coupling reagents commonly used in peptide synthesizing. The coupling reagents disclosed included dicyclohexylcarbodiimide (optionally in the presence of 1-hydroxybenzotriazole), diphenylphosphoryl azide or N, N - carbonyldiimidazole. Suitable inert solvents for the reaction included an ether, halogenated hydrocarbons, amides or ketones.

The synthesis of N-{4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)-ethyl]phenyl}-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide and its physiologically acceptable salts and solvates is also

disclosed by Ne'rina Dodic *et al.*, Journal of Medicinal Chemistry, 1995, Vol. 38 No. 13, pages 2418-2426. The synthesis route in Dodic utilized the same coupling reagents as set forth in WO 92/12132. In the Dodic article, example 84 corresponds to N-{4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)-ethyl]phenyl}-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide.

SUMMARY OF THE INVENTION

The present invention provides an improved process of synthesizing the multidrug-resistant inhibitor, hydrochloride salt of N-{4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)-ethyl]phenyl}-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide. This process eliminates the use of prior art coupling reagents which produced a water insoluble diisopropyl urea by-product during the coupling of the intermediates. This urea by-product was not easily removed. The prior art also suggested using a chlorinated solvent, i.e., dichloromethane, during the intermediate synthesis stages.


The present invention further provides an improved process wherein the by-product, tetramethyl urea, formed from the coupled intermediates is water soluble and easily removed. Furthermore, the present inventive process eliminates the use of chlorinated solvents and allows for direct crystallization of the intermediates from the reaction mixture.

The present invention further provides an improved process having increased throughput and products having higher purity.


The present invention includes synthetic steps and intermediates involved in a scheme of synthesizing the hydrochloride salt, N-{4-[2-(1,2,3,4-

tetrahydro-6,7-dimethoxy-2-isoquinoliny]ethyl]phenyl]-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide of the following formula (I)

Scheme 1:



Scheme 2:



DETAILED DESCRIPTION OF THE INVENTION

In the description and examples that follow throughout the specification, the following abbreviations may be used: THF (tetrahydrofuran); DMF (N,N-dimethyl formamide); TBTU (2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate); DMSO (dimethylsulfoxide); g (grams); mL (milliliters); mp (melting point); ¹H-NMR (proton nuclear magnetic resonance); ppm (parts per million); MHz (Megahertz); and eq. (molar equivalents). Unless otherwise noted, all temperatures are expressed in °C (degrees centigrade).

¹H-NMR spectra were measured in DMSO using a Bruker ARX-300 MHz instrument. Chemical shifts are expressed in ppm in reference to an internal standard such as DMSO. Apparent multiplicities are designated s, singlet; d, doublet; t, triplet; m, multiplet; br s, broad singlet. Melting points were determined on a Perkin Elmer DSC 7. HPLC data was collected on a Hitachi L-6200 A pump, L-4000 UV detector and a D-2500 integrator.


The materials used in the synthesis process are available from Aldrich Chemical Company, which is located in Milwaukee, Wisconsin. The peptide coupling reagent, TBTU, is available from Peboc, Llangefui, Anglesey, Gwynedd, which is located in Wales, UK. The filtering aid, Harborlite, is available from Harborlite, which is located in Hull, UK.

The synthesis process is carried out in the presence of coupling reagents used in peptide synthesis, such as tetramethyluronium salt based peptide coupling agents and tetramethyluronium salt based acid activating agents. Exemplary agents include, TBTU, O-(Benzotriazole-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate, O-(7-Azabenzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate and O-(1,2-Dihydro-2-oxo-1-


pyridyl)-N,N,N',N'-tetramethyluronium tetrafluoroborate. Other acid activating reagents, such as 1,1'-carbonyldiimidazole, can be utilized in the synthesis process. The synthesis process can be carried out in a alkylamine base, such as triethylamine and diisopropylamine in addition to aromatic amine bases such as pyridine. Suitable solvents for the synthesis process include polar aprotic solvents, such as DMF or 1-methyl-2-pyrrolidinone as well as acetonitrile.

The starting compounds of Scheme 1, to prepare the compound of formula (II), are prepared in accordance with stages 1 and 2 below:

Stage 1



Stage 2




In stage 1, the methoxydiacid of formula (IIc) is obtained by forming a suspension of an 2-amino-3-methoxybenzoic acid (IIa), 2-bromobenzoic acid (IIb) potassium carbonate and copper powder which is stirred in ethanol and heated to reflux for at least 0.5 hours, preferably 1 hour. The suspension is cooled to 20-25° C and water added. A filtering aid is added and the mixture filtered. The filter bed is washed with water and the combined filtrates adjusted to pH 2-3 by the addition of concentrated hydrochloric acid over a

period of about 30 minutes. The resulting suspension is then aged in the reactor at 10-12°C for at least 1 hour and the solid product collected by filtration, washed with water and dried in a vacuum at 50°C.


In stage 2, the methoxydiacid of formula (IIc), formed in stage 1 is mixed with acetonitrile and heated at reflux and phosphorous oxychloride is added dropwise over 2 hours. The resulting mixture is heated at reflux for at least 1 hour preferably 2 hours. This mixture is then cooled to 10-15°C. Water is added and the resultant thick slurry is heated at reflux for 2.5 hours. The slurry is then cooled to 10°C and filtered. The product, acridone acid of formula (II), is washed with water followed by acetonitrile and dried in vacuum at 50°C for 48 hours.

The starting compounds of Scheme 1, to prepare the compound of formula (III), are prepared in accordance with stages 3 and 4 below:

Stage 3



Stage 4




In stage 3, the nitrophenethyl isoquinoline of formula (IIIc) is obtained by mixing 4-nitrophenethyl bromide, of formula (IIa), 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride, of formula (IIb), anhydrous potassium carbonate and potassium iodide in DMF. The mixture is heated at 70°C with stirring under a nitrogen atmosphere for 18 hours. The mixture is cooled to 50°C and methanol added. The mixture is further cooled to 30°C and water added. The mixture is then stirred at 10°C for 1 hour, filtered, and the product washed with water and dried at 45°C under vacuum.

In stage 4, the nitrophenethyl isoquinoline, or formula (IIIc), formed in stage 3 is stirred in a solution of ethanol and THF at 15-20° and purged with nitrogen and a Pd/C catalyst added. After re-purging with nitrogen, the stirring is stopped and the mixture is purged with hydrogen. Stirring is resumed and the mixture maintained at 15-25°C until hydrogen uptake is complete. The reaction mixture is filtered, the filters rinsed with THF and the combined filtrates concentrated to an appropriate volume under vacuum at 55-65°C. Hexane is added over a 20-40 minute period and the resulting slurry cooled to 0°C. After stirring at 0°C for 1.5 hours, the suspension is filtered, the solid washed with hexane and dried in a vacuum oven at 40-45°C. The resulting solid is aminophenethyl isoquinoline of formula (III).

The intermediate compounds of scheme 1, to prepare the multidrug inhibitor free base compound of formula (IV) is prepared in accordance with stage 5.

Stage 5




In stage 5, Scheme 2, a mixture of the intermediate compounds, acridone acid of formula (II) and aminophenethyl isoquinoline of formula (III) are stirred in DMF under a nitrogen atmosphere until complete dissolution is accomplished in about 10 minutes. A peptide coupling reagent, TBTU, is added followed by triethylamine, a base. The solution is stirred at 20-25°C for 1-2 hours until the reaction is complete. A mixture of isopropanol-water is added and the mixture stirred at 20-25°C for 30 -60 minutes until crystallization occurs. The resulting slurry, MDRI free base of formula (IV), is filtered and washed with methanol, followed by water and dried in a vacuum oven at up to 50°C.

The crude MDRI free base is then recrystallized by dissolving in DMF at 35-40°C followed by the addition of ethanol over a period of about 4 hours at 35-40°C. The resulting slurry is then cooled at 10°C for 1 hour and filtered.

The product is washed with methanol and dried in a vacuum oven at up to 50°C.

The compound of formula (I) in scheme 2, wherein the MDRI free base of formula (IV) is converted into a hydrochloride salt of formula (I) in accordance with stage 6.

Stage 6



In stage 6, a stirred suspension of the MDRI free base of formula (IV) in glacial acetic acid is heated to 65-70°C and the resulting solution hot filtered. The solution is then reheated to 70°C and hot, pre-filtered ethanol is added. Pre-filtered concentrated hydrochloric acid is then added over a period of about 30 minutes. The resulting solution is stirred at 70°C until crystals form, about 20 minutes, and then cooled to 20-25°C over 1 hour and filtered. The resulting filter cake is washed with ethanol and dried for at least 70 hours at 65°C in a vacuum oven.

EXAMPLES

Example 1

Methoxydiacid (Formula IIc)

A suspension of 164.6 g (1 molar eq) of 2-amino-3-methoxybenzoic acid (formula IIa), 217.7 g (1.1 molar eq) of 2-bromobenzoic acid (formula IIb), 272.3 g (2.0 molar eq) of potassium carbonate and 12.5 g (0.2 molar

eq) of copper powder is stirred in 1500 mL of ethanol and heated to reflux for 0.5 - 3 hrs, preferably 1 hour. The suspension is cooled to 20-25°C and 1450 mL of water is added. A filtering aid, 15 g, is added and the mixture filtered. The filter bed is washed with 875mL of water and the combined filtrates adjusted to a pH of 2-3 by the addition of 250 mL of concentrated hydrochloric acid over a period of about 30 min. The resulting suspension is then aged in the reactor at 10-12°C for at least 1 hour and the solid product collected by filtration, washed with 1450 mL of water and dried in a vacuum at 50°C. The expected yield of the titled compound is 95% theoretical.

¹H-NMR (300 MHz): δ 3.7 (s, 3H, OMe); 6.1-7.9 (m, 7H, Ar); 9.7 (br s, 1H, COOH); 11.1 (br s, 1H, COOH) ppm. Mp is 254-256°C.

Example 2

Acridone acid (Formula II)

A mixture of 280.0 g (1 molar eq) of methoxydiacid (formula IIC) in 2300 mL of acetonitrile is heated at reflux and 200 mL (2.2 molar eq) of phosphorous oxychloride added dropwise over 2 hours. The mixture is heated at reflux for 1-5 hours, preferably 2 hours. The mixture is then cooled to 10-15°C. To the mixture 1700 mL of water is added and the resultant thick slurry is heated at reflux for 2.5 hours. The slurry is then cooled to 10°C and filtered. The resulting product is washed twice with 850 mL of water, washed twice with 850 mL of acetonitrile and dried in vacuum at 50°C for 48 hours. The expected yield of the titled compound is 95% theoretical.

¹H-NMR (300 MHz): δ 4.0 (s, 3H, OMe); 6.9-8.5(m, 7H, 6Ar and NH); 10.1 (br s, 1H, COOH) ppm. Mp is 354-362°C.

Example 3

Nitrophenethyl isoquinoline (Formula IIIC)

A mixture of 302 g (1 molar eq) of 4-nitrophenethyl bromide (formula IIIa), 302 g (1 molar eq) of 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride (formula IIIb), 181 g (1.1 molar eq) of anhydrous potassium carbonate and 45 g (0.2 molar eq) of potassium iodide in 1500 mL of DMF is heated at 70°C with stirring under a nitrogen atmosphere for 12-24 hours, preferably 18 hours. The mixture is cooled to 50°C and 450 mL of methanol is added. The mixture is then cooled to 30°C before adding 3000 mL of water. The mixture is stirred at 10°C for 1 hour, filtered and the product washed twice with 1500 mL of water and dried at 45°C under vacuum. The expected yield of the titled compound is 90% theoretical.

¹H-NMR (300 MHz): δ 2.53-3.0 (m, 8H, CH₂); 3.5 (s, 2H, N-CH₂-Ph); 3.7 (s, 6H, Ome); 6.4 (d, 2H, Ar isoquinoline); 7.2 and 7.9 (dd, 4H, Ar PHNO₂) ppm. Mp is 116-118°C.

Example 4

Aminophenethyl isoquinoline (Formula III)

A stirred solution of 230.0 g (1 molar eq) of nitrophenethyl isoquinoline (formula IIIc) in 1700 mL of ethanol and 1700 mL of THF at 15-20°C is purged with nitrogen and 46 g of Pd/C catalyst is added. After re-purging with nitrogen, the stirring is stopped and the mixture is purged with hydrogen. Stirring is resumed and the mixture is maintained at 15-25°C until hydrogen uptake is complete (1-20 hours). The reaction mixture is filtered, the filter is rinsed with 900 mL of THF and the combined filtrates are then concentrated to 7 volumes under vacuum at 55-65°C. To the concentrated filtrate is added 2000 mL of hexane over 20-40 minutes, and the resulting slurry cooled to 0°C. After stirring at 0°C for 1.5 hours the suspension is filtered, the solid washed with 450 mL of hexane and dried in a vacuum oven at 40-45°C. The expected yield of the titled compound is 89% theoretical.

$^1\text{H-NMR}$ (300 MHz) δ 2.5-3.0 (m, 8H, CH_2); 3.5 (s, 2H, $\text{N-CH}_2\text{-Ph}$); 3.7 (s, 6H, OMe); 6.4 (d, 2H, Ar isoquinoline); 7.2 and 7.9 (dd, 4H, Ar PHNO_2) ppm. Mp is 123-126°C.

Example 5

MDRI free base-(Formula IV)

A mixture of 200.0 g (1 molar eq) of acridone acid (formula II) and 232.1 g (1 molar eq) of aminophenethyl isoquinoline (formula III) is stirred in 2000 mL of DMF at 20-25°C until complete dissolution is accomplished in about 10 minutes. To this mixture 250.5 g (1.05 molar eq) of TBTU, a peptide coupling reagent, is added, followed by 218 mL (2.1 molar eq) of triethylamine, a base. The resulting solution is stirred at 20-25°C for 1-2 hours until the reaction is complete. A 1:1 mixture of 1000 mL of isopropanol and 1000 mL of water is added and the mixture stirred at 20-25°C until crystallization occurs (30-60 minutes). The resulting slurry is filtered and washed with 1600 mL of methanol, followed by washing with 1600 mL of water. The slurry is dried in a vacuum oven at up to 50°C.

The crude MDRI free base (formula IV) is then recrystallized by dissolving in 1800 mL of DMF at 35-40°C, followed by the addition of 3600 mL of ethanol over a period of about 4 hours at 35-40°C. The resulting slurry is then cooled to 10°C for 1 hour and filtered. The product is washed with 1000 mL of methanol and dried in a vacuum oven at up to 50°C. The expected yield of the titled compound is 70-75% theoretical.

$^1\text{H-NMR}$ (300 MHz): δ 2.40-2.95 (m, 8H, CH_2); 3.58 (s, 2H, $\text{N-CH}_2\text{-Ph}$); 3.72 (s, 6H, 2OMe); 4.05 (s, 3H, OMe acridone); 6.78 (d, 2H, Ar isoquinoline); 7.20-7.88 (m, 8H, Ar); 8.48 (t, 2H, H_2 and H_7 acridone); 10.60 (br s, 1H, CONH); 12.32 (br s, 1H, NH acridone) ppm. Mp is 215-220°C.

Example 6

MDRI drug substance (Formula I)

A stirred suspension of 20.0g (1 molar eq) of MDRI free base (formula IV) in 80 mL of glacial acetic acid is heated to 65-70°C and the resulting solution hot filtered. The solution is then reheated to 70°C and 240 mL of pre-filtered ethanol (70°C) is added. To this solution, 4.4 mL (1.5 molar eq) of pre-filtered concentrated hydrochloric acid is added over a period of about 30 minutes. The resulting solution is stirred at 70°C until crystals form, about 20 minutes, and cooled to 20-25°C over a 1 hour period and filtered. The resulting filter cake is twice washed with 120 mL of ethanol and dried for at least 70 hours at 65°C in a vacuum oven. The expected yield of the titled compound is 90% theoretical.


¹H-NMR (500 MHz, DMSO-d₆) δ 12.31 (s, 1H), 10.98 (br s, 1H), 10.75 (s, 1H), 8.53 (dd, 1H), 8.52 (ddd, 1H), 7.82 (ddd, 1H), 7.76 (m, 2H), 7.44 (dd, 1H), 7.40 (dd, 1H), 7.38 (m, 2H), 7.28 (dd, 1H), 6.84 (s, 1H), 6.81 (s, 1H), 4.52 (d, 1H), 4.29 (dd, 1H), 4.06 (s, 3H) 3.77 (m, 1H), 3.76 (s, 3H), 3.75 (s, 3H), 3.45 (m, 2H), 3.33 (m, 1H), 3.19 (m, 1H), 3.19 (m, 2H), 2.96 (dt, 1H) ppm. Mp is 240 °C.

Anal. Calc'd. for C₃₄H₃₃N₃O₅·HCl·0.5H₂O: C, 67.04; H, 5.57; N, 6.90; Cl, 5.82;

Found: C, 67.00; H, 5.78; N, 6.89; Cl, 5.87.


Claims:

1. A method of synthesizing a compound of formula (IV)




which comprises the steps of:

- (i) reacting a compound of formula (II):




with a compound of formula (III):




in the presence of a coupling reagent to yield a free base of formula (IV);

- (ii) optionally converting the compound of formula (IV) to the HCl salt of formula (I).




2. The method of claim 1, wherein the coupling reagent is a tetramethyluronium based peptide coupling reagent.
3. The method of claim 2, wherein the coupling reagent is 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate.
4. The method of claim 2, further containing an amine base.
5. The method of claim 4, wherein the amine base is triethylamine.
6. The method of claim 1, wherein the reaction takes place at about 20-25°C.
7. The method of claim 1, wherein the reaction takes place in a period of at least one hour.
8. The method of claim 1, wherein said coupling step is conducted at about 20-25°C.
9. The method of claim 1, wherein compounds (II) and (III) are dissolved in a polar aprotic solvent prior to adding the coupling agent.
10. The method of claim 9, wherein the polar aprotic solvent is dimethyl formamide.
11. A method of synthesizing a compound of formula (I)




which comprise the steps of:

i) reacting an acridone acid of formula (II):


-16-



and an aminophenethyl isoquinoline of formula (III):



with a tetramethyluronium based peptide coupling agent
in the presence of an amine base to yield a free base of formula (IV)
and;



ii) converting the free base of formula (IV) to the compound of
formula (I).

12. The method of claim 11, wherein the free base of formula (IV) is
converted in the presence of glacial acetic acid.

13. The method of claim 11, wherein said coupling step occurs in about 3
hours.

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 98/02991

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07D219/06 A61K31/435

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 92 12132 A (GLAXO LAB SA) 23 July 1992 cited in the application see example 1	1,6-10
Y	see page 13, line 1-12 ---	1-13
X	NERINA DODIC ET AL: "SYNTHESIS AND ACTIVITY AGAINST MULTIDRUG RESISTANCE IN CHINESE HAMSTER OVARY CELLS OF NEW ACRIDONE-4-CARBOXAMIDES" JOURNAL OF MEDICINAL CHEMISTRY, vol. 38, no. 13, 23 June 1995, pages 2418-2426, XP000565701 cited in the application see example 84	1,6-10
Y	see page 2425, column 1, paragraph 4 ---	1-13
	--- -/--	

☒ Further documents are cited in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

18 September 1998

Date of mailing of the international search report

25/09/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Lauro, P

INTERNATIONAL SEARCH REPORT

Inter. Appl. No.
PCT/EP 98/02991

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>CARPINO L A: "1-HYDROXY-7-AZABENZOTRIAZOLE AN EFFICIENT PEPTIDE COUPLING ADDITIVE" JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 115, no. 10, 1 January 1993, page 4397/4398 XP002010111 see the whole document -----</p>	1-13

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 98/02991

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9212132 A	23-07-1992	AT 153660 T	15-06-1997
		AU 652996 B	15-09-1994
		AU 1154392 A	17-08-1992
		CA 2100258 A	12-07-1992
		CZ 9301378 A	16-02-1994
		DE 69220037 D	03-07-1997
		DE 69220037 T	06-11-1997
		DK 569380 T	22-12-1997
		EP 0494623 A	15-07-1992
		EP 0569380 A	18-11-1993
		ES 2104887 T	16-10-1997
		FI 933149 A	09-07-1993
		GR 3024525 T	28-11-1997
		HU 68856 A	28-08-1995
		HU 9500524 A	30-10-1995
		IL 100631 A	12-09-1996
		JP 2783680 B	06-08-1998
		JP 6506440 T	21-07-1994
		MX 9200109 A	01-09-1992
		NO 300267 B	05-05-1997
		NZ 241278 A	26-05-1994
		PL 168202 B	31-01-1996
		SG 45403 A	16-01-1998
		SK 73093 A	12-01-1994
		US 5604237 A	18-02-1997

THIS PAGE BLANK (USPTO)